HopeStage
Back to all studies
CompletedNCT00314639

Modafinil added to treatment for cognitive difficulties in schizophrenia

About this titleRead the official source — NCT00314639
Medication studyAges 18+Canada
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
QuébecSee all locations and recruitment
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateSeptember 2005
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
Laval University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
Canada
Age range
Over 18 Years
Official registry ID
NCT00314639
Official title
Show the full official title

The Impact of Modafinil as an Adjunctive to a Second Generation Antipsychotic on Cognitive Functioning in Schizophrenia and Schizophrenia Spectrum Psychosis.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Québec

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Laval University, a university.

Did this study involve medication?

Yes. The study involved medication, including modafinil.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies